KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EBT (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed EBT for 7 consecutive years, with $35.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 2942.63% year-over-year to $35.7 million, compared with a TTM value of $114.2 million through Dec 2025, up 1432.72%, and an annual FY2025 reading of $114.2 million, up 1432.72% over the prior year.
  • EBT was $35.7 million for Q4 2025 at Aurinia Pharmaceuticals, up from $32.0 million in the prior quarter.
  • Across five years, EBT topped out at $35.7 million in Q4 2025 and bottomed at -$50.4 million in Q1 2021.
  • Average EBT over 5 years is -$12.1 million, with a median of -$12.6 million recorded in 2023.
  • The sharpest move saw EBT crashed 92.48% in 2021, then skyrocketed 2942.63% in 2025.
  • Year by year, EBT stood at -$32.6 million in 2021, then rose by 22.72% to -$25.2 million in 2022, then decreased by 4.86% to -$26.4 million in 2023, then skyrocketed by 104.44% to $1.2 million in 2024, then surged by 2942.63% to $35.7 million in 2025.
  • Business Quant data shows EBT for AUPH at $35.7 million in Q4 2025, $32.0 million in Q3 2025, and $22.2 million in Q2 2025.